Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 2
2017 2
2018 4
2019 10
2020 5
2021 2
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Ericsson PG, Lee KM, Nixon MJ, Schwarz LJ, Sanders ME, Dugger TC, Cruz MR, Behdad A, Cristofanilli M, Bardia A, O'Shaughnessy J, Nagy RJ, Lanman RB, Solovieff N, He W, Miller M, Su F, Shyr Y, Mayer IA, Balko JM, Arteaga CL. Formisano L, et al. Among authors: jansen vm. Nat Commun. 2019 Mar 26;10(1):1373. doi: 10.1038/s41467-019-09068-2. Nat Commun. 2019. PMID: 30914635 Free PMC article.
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.
Tolaney SM, Toi M, Neven P, Sohn J, Grischke EM, Llombart-Cussac A, Soliman H, Wang H, Wijayawardana S, Jansen VM, Litchfield LM, Sledge GW. Tolaney SM, et al. Among authors: jansen vm. Clin Cancer Res. 2022 Apr 14;28(8):1500-1506. doi: 10.1158/1078-0432.CCR-21-3276. Clin Cancer Res. 2022. PMID: 35121623 Free PMC article. Clinical Trial.
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer.
Hurvitz SA, Martin M, Press MF, Chan D, Fernandez-Abad M, Petru E, Rostorfer R, Guarneri V, Huang CS, Barriga S, Wijayawardana S, Brahmachary M, Ebert PJ, Hossain A, Liu J, Abel A, Aggarwal A, Jansen VM, Slamon DJ. Hurvitz SA, et al. Among authors: jansen vm. Clin Cancer Res. 2020 Feb 1;26(3):566-580. doi: 10.1158/1078-0432.CCR-19-1425. Epub 2019 Oct 15. Clin Cancer Res. 2020. PMID: 31615937 Free PMC article. Clinical Trial.
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR, Kim D, Luo F, Mao P, Helvie K, Kowalski KJ, Nayar U, Waks AG, Parsons SH, Martinez R, Litchfield LM, Ye XS, Yu C, Jansen VM, Stille JR, Smith PS, Oakley GJ, Chu QS, Batist G, Hughes ME, Kremer JD, Garraway LA, Winer EP, Tolaney SM, Lin NU, Buchanan SG, Wagle N. Wander SA, et al. Among authors: jansen vm. Cancer Discov. 2020 Aug;10(8):1174-1193. doi: 10.1158/2159-8290.CD-19-1390. Epub 2020 May 13. Cancer Discov. 2020. PMID: 32404308 Free PMC article. Clinical Trial.
Landscape of baseline and acquired genomic alterations in circulating tumor DNA with abemaciclib alone or with endocrine therapy in advanced breast cancer.
Goetz MP, Hamilton EP, Campone M, Hurvitz SA, Cortes J, Johnston S, Llombart-Cussac A, Kaufman PA, Toi M, Jerusalem G, Graham H, Wang H, Jansen VM, Litchfield LM, Martín M. Goetz MP, et al. Among authors: jansen vm. Clin Cancer Res. 2023 Oct 27. doi: 10.1158/1078-0432.CCR-22-3573. Online ahead of print. Clin Cancer Res. 2023. PMID: 37889120 Free article.
SETD2 loss sensitizes cells to PI3Kβ and AKT inhibition.
Terzo EA, Lim AR, Chytil A, Chiang YC, Farmer L, Gessner KH, Walker CL, Jansen VM, Rathmell WK. Terzo EA, et al. Among authors: jansen vm. Oncotarget. 2019 Jan 18;10(6):647-659. doi: 10.18632/oncotarget.26567. eCollection 2019 Jan 18. Oncotarget. 2019. PMID: 30774762 Free PMC article.
29 results